AstraZeneca stock falls after FDA panel votes against new cancer drug
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
AI Summary
An FDA advisory panel voted 6-3 against approving AstraZeneca's experimental breast cancer drug camizestrant, citing concerns that clinical trial data didn't prove early switching to the drug improved long-term survival compared to standard treatments. AstraZeneca's stock fell 2% following the vote, though the panel acknowledged the drug's efficacy and safety profile while questioning whether the trial design adequately demonstrated benefits of early intervention. The FDA generally follows advisory panel recommendations but is not bound by them, and AstraZeneca stated it will continue working with regulators on the application.